ArticleBMC microbiology2025
Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- Use of reverse dot blot hybridization DNA-array and targeted next-generation sequencing for the detection of drug resistance in patients with tuberculosis: a prospective diagnostic accuracy study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Whole-Genome Sequencing and Phenotypic Drug Susceptibility Testing of Bedaquilin, Delamanid, Pretomanid, and Linezolid in Drug-ResistantPathogens (Basel, Switzerland) · 2026Article
- A Comprehensive Review of Genetic Mechanisms ofInfection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSo far, there are scarce data on resistance to delamanid (DLM), bedaquiline (BDQ), and linezolid (LZD) antibiotics and related gene mutations in multidrug-resistant Mycobacterium tuberculosis (MDR M. tuberculosis) from Iran. Hence, this study aimed to investigate the DLM, BDQ, and LZD resistance rates and related gene mutations in MDR M. tuberculosis in regional tuberculosis reference laboratories of Iran.
methodsIn this cross-sectional study, MDR M. tuberculosis isolates (resistant to antibiotics rifampicin and isoniazid) were collected from sputum samples of tuberculosis patients referred to several regional tuberculosis reference laboratories in Iran. The resistance against DLM, BDQ, and LZD antibiotics was evaluated using the proportion method on the Middlebrook 7H11 agar culture medium. The minimum inhibitory concentration (MIC) of three antibiotics was evaluated using the broth microdilution method. Mutations in genes that contributed to resistance to antibiotics DLM (fbiA, fbiC, ddn, fgd1), BDQ (atpE, pepQ, Rv0678), and LZD (rrl and rplC) were investigated by polymerase chain reaction (PCR) and sequencing.
resultsThis study examined 29 clinical MDR M. tuberculosis isolates. These isolates were collected from 68.9% (20/29) males and 31.1% (9/29) females with a mean age of 40 years (ranged 30–70 years). The resistance rate to DLM, BDQ, and LZD was 27.6% (n = 8/29), 0.0% (n = 0/29), and 6.8% (n = 2/29), respectively. The range of MIC for DLM was 0.12–0.48 µg/ml. Meanwhile, the 2 LZD-resistant isolates showed MIC of 2.0 µg/ml. All MDR M. tuberculosis isolates with phenotypic resistance to DLM (8 isolates) contained mutations in one of the fgd1, fbiA, and fbiC genes. A mutation was identified in the 1090 bp fragment of the fgd1 gene at position 839 in five isolates. Additionally, the 2386 bp fragment of the fbiC gene revealed mutations at positions 266 and 952 in three isolates. Also, two DLM-resistant isolates exhibited two mutations at position 145 and 960 in the 1136 bp fragment of fbiA. No genetic mutations were detected in ddn, atpE, pepQ, and Rv0678 genes. Two LZD-resistant isolates exhibited mutations in the rplc gene at position 460 within the 933 bp fragment, and in the rrl gene at positions 2576 and 2814 within the 1772 bp fragment.
conclusionThis study found multiple mutations in the fgd1, fbiA, fbiC, rplc, and rrl genes that were responsible for the development of DLM and LZD resistance in MDR M. tuberculosis isolates in Iran. More research is needed to understand the underlying mechanisms of resistance to these antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.